Find trials
Search tips

Kinetics of Clostridium Difficile Toxin PCR Positivity and Prediction of Recurrent Infection following Metronidazole or Vancomycin Therapy

Overview

About this study

 

This study is to see if PCR test developed at Mayo Clinic to diagnosis C. Difficile infections is able to predict the risk of recurrent infection.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

 

Inclusion Criteria:       

  • Patients between 18 and 99 who are diagnosed with CDI via PCR testing and consent will be eligible for enrollment.  
  • Subjects will be recruited from the lab in a consecutive fashion.

 

Exclusion Criteria:      

  • Subject is not capable of submitting stool samples.           

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Darrell Pardi, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

More about research at Mayo Clinic

.
CLS-20311343

Mayo Clinic Footer